PMID- 19561397
OWN - NLM
STAT- MEDLINE
DCOM- 20100610
LR  - 20211020
IS  - 2092-6413 (Electronic)
IS  - 1226-3613 (Print)
IS  - 1226-3613 (Linking)
VI  - 41
IP  - 10
DP  - 2009 Oct 31
TI  - Interleukin-1beta promotes the expression of monocyte chemoattractant protein-1 
      in human aorta smooth muscle cells via multiple signaling pathways.
PG  - 757-64
LID - 10.3858/emm.2009.41.10.082 [doi]
AB  - Monocyte chemoattractant protein-1 (MCP1) plays a key role in monocyte/macrophage 
      infiltration to the sub-endothelial space of the blood vessel wall, which is a 
      critical initial step in atherosclerosis. In this study, we examined the 
      intracellular signaling pathway of IL-1beta-induced MCP1 expression using various 
      chemical inhibitors. The pretreatment of a phosphatidylcholine (PC)-specific PLC 
      (PC-PLC) inhibitor (D609), PKC inhibitors, or an NF-kapaB inhibitor completely 
      suppressed the IL-1beta-induced MCP1 expression through blocking NF-gammaB 
      translocation to the nucleus. Pretreatment with inhibitors of tyrosine kinase or 
      PLD partially suppressed MCP1 expression and failed to block nuclear NF-kappaB 
      translocation. These results suggest that IL-1beta induces MCP1 expression 
      through activation of NF-kappaB via the PC-PLC/PKC signaling pathway.
FAU - Lim, Jun Hee
AU  - Lim JH
AD  - Department of Immunology and Chronic Disease Research Center and Institute for 
      Medical Science, School of Medicine, Keimyung University, Taegu 700-712, Korea.
FAU - Um, Hee Jung
AU  - Um HJ
FAU - Park, Jong-Wook
AU  - Park JW
FAU - Lee, In-Kyu
AU  - Lee IK
FAU - Kwon, Taeg Kyu
AU  - Kwon TK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Exp Mol Med
JT  - Experimental & molecular medicine
JID - 9607880
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Estrenes)
RN  - 0 (Interleukin-1beta)
RN  - 0 (NF-kappa B)
RN  - 0 (Norbornanes)
RN  - 0 (Pyrrolidinones)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Thiocarbamates)
RN  - 0 (Thiones)
RN  - 112648-68-7 
      (1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione)
RN  - 5QC1Z07M77 (tricyclodecane-9-yl-xanthogenate)
RN  - DH2M523P0H (Genistein)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 3.1.- (Phospholipases)
SB  - IM
MH  - Active Transport, Cell Nucleus/drug effects
MH  - Aorta/pathology
MH  - Atherosclerosis/immunology/metabolism
MH  - Bridged-Ring Compounds/pharmacology
MH  - Cell Nucleus/*metabolism
MH  - Cells, Cultured
MH  - Chemokine CCL2/*biosynthesis
MH  - Estrenes/pharmacology
MH  - Genistein/pharmacology
MH  - Humans
MH  - Interleukin-1beta/metabolism
MH  - Myocytes, Smooth Muscle/drug effects/immunology/*metabolism/pathology
MH  - NF-kappa B/*metabolism
MH  - Norbornanes
MH  - Phospholipases/antagonists & inhibitors
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Pyrrolidinones/pharmacology
MH  - Recombinant Proteins/metabolism
MH  - Signal Transduction/*drug effects
MH  - Thiocarbamates
MH  - Thiones/pharmacology
PMC - PMC2772978
EDAT- 2009/06/30 09:00
MHDA- 2010/06/11 06:00
PMCR- 2009/10/31
CRDT- 2009/06/30 09:00
PHST- 2009/06/30 09:00 [entrez]
PHST- 2009/06/30 09:00 [pubmed]
PHST- 2010/06/11 06:00 [medline]
PHST- 2009/10/31 00:00 [pmc-release]
AID - 10.3858/emm.2009.41.10.082 [doi]
PST - ppublish
SO  - Exp Mol Med. 2009 Oct 31;41(10):757-64. doi: 10.3858/emm.2009.41.10.082.